

List of Drugs in Development for Neurodegenerative Diseases

Frauke Fischer^a Mark Matthisson^b Paul Herrling^a

^aCorporate Research, Novartis International AG; ^bNovartis Pharma AG, Basel, Switzerland

Neurodegenerative diseases are an increasingly important issue in our society. There are, however, still many obstacles on the way to finding methods for cure. This table is intended to give an overview over neurodegenerative drugs that are currently in research and development in order to give the reader an idea about the complexity of drug discovery in this field.

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
1	Discovery	University of South Florida	(-)-Epigallocatechin-3-gallate	Neurodegenerative disease	IL synthesis modulator; Protein kinase C modulator; TACE modulator	Cell cycle inhibitor
2	Discovery	Fujimoto Seiyaku Co Ltd	(R)-(-)-BPAP	Neurodegenerative disease	Neurotransmitter modulator	Neuroprotectant
3	Phase 2 Clinical	Carlbiotech Ltd	106362-32-7	HIV associated dementia; Neurodegenerative disease	peptide-T	Nootropic agent
4	Discontinued	AstraZeneca plc	128298-28-2; Remacemide	Huntington's Chorea; Cerebrovascular ischemia,	NMDA receptor antagonist	Neuroprotectant
5	Phase 3 Clinical	Cardinal Health Inc	14611-51-9; Selegiline; Zydys	Parkinson's disease; Cerebrovascular ischemia	MAO B inhibitor	Neuroprotectant
6	Discovery	National Institutes of Health	4-Cl-kynurenine	Neurodegenerative disease	NMDA receptor antagonist	Neuroprotectant
7	Research Tool	Abbott Laboratories	A-134974	Epilepsy; Neurodegenerative disease	Adenosine kinase inhibitor	Anticonvulsant agent
8	Discovery	Abbott Laboratories	A-366833; A-35380	Alzheimer's disease; Pain; Neurodegenerative disease; Nicotine use disorder; Anxiety disorder; Schizophrenia	Nicotinic ACh agonist, Neuronal nAChR ligand	Nootropic agent; Anxiolytic; Antipsychotic; Analgesic
9	Discontinued	Abbott Laboratories	A-72055	Neurodegenerative Disease	Muscarinic ACh agonist	Nootropic agent

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
10	Discontinued	American Biogenetic Sciences Inc	ABS-205	Neurodegenerative disease; Cognitive disorder	Cell adhesion molecule modulator; Neuronal growth factor	
11	Discovery	ACADIA Pharmaceuticals Inc	AC-184897	Neurodegenerative disease; Carcinoma	Nuclear receptor agonists	Anticancer; Neuroprotectant
12	Discovery	ACADIA Pharmaceuticals Inc	AC-90222	Alzheimer's Disease	Muscarinic M1 agonist	Nootropic agent
13	Discontinued	Cocensys Inc, Novartis	ACEA-1021	Epilepsy; Head trauma; Pain	NMDA,/ Glycine antagonist	Neuroprotectant, Anticonvulsant
14	Discovery	National Institutes of Health	ADCI	Neurodegenerative disease	NMDA and sodium channel antagonist	Neuroprotectant; Anticonvulsant agent
15	Discovery	Aegera Therapeutics Inc	AEG-3482 series	Multiple sclerosis; Cerebrovascular ischemia; Cancer	Apoptose inhibitors	Neuroprotectant
16	Discovery	AGY Therapeutics	AGY-110	Alzheimer's disease; Schizophrenia, Major depressive disorder	Unclassified enzyme inhibitor	Nootropic agent
17	Discovery	AGY Therapeutics	AGY-207	Cerebrovascular ischemia	Unclassified enzyme inhibitor	Neuroprotectant
18	No Development Reported	Cortex/Alkermes	AK-275; Vasolex	Cerebral infarction; Ischemia	Calpain inhibitor	Neuroprotectant; Vasoprotectant
19	Phase 2 Clinical	VUFB	Alaptid	Alzheimer's disease	Melanotropin-inhibiting factor (MIF)-1 analog	Nootropic agent
20	No Development Reported	NPS Allelix Corp	ALE-0540	Nervous system injury; Pain; Neurodegenerative disease	NGF antagonist	Neuroprotectant; Analgesic
21	Discovery	AMRAD Corp Ltd	AM-36	Cerebrovascular ischemia; Alzheimer's disease, Spinal chord injury	Sodium channel blocker	Neuroprotectant; Antioxidant agent
22	Discovery	Annovis Inc	AMPA antagonists, Annovis	Epilepsy; Neurodegenerative disease; Schizophrenia; Cerebrovascular ischemia	AMPA receptor antagonist	Neuroprotectant; Antipsychotic; Anticonvulsant agent
23	Discovery	University of California; Cortex; NV Organon; Servier	AMPAKINES	Dementia; Schizophrenia; Alzheimer's disease	AMPA receptor modulator	Neuroprotectant; Antidepressant, Antipsychotic
24	Phase 1 Clinical	Axonyx Inc / Serono	Amyloid-inhibiting peptides	Alzheimer's disease; Neurodegenerative disease	Beta amyloid generation inhibitor	Anti-amyloidogenic
25	Discontinued	Elan Pharmaceuticals Inc	AN-1792	Alzheimer's disease	Amyloid protein deposit inhibitor; Vaccine	Immunomodulator
26	Discovery	Paracelsian Inc	Andrographolide	Neurodegenerative disease		Neuroprotectant; Anti-inflammatory
27	Phase 3 Clinical	Apollo Biopharmaceutics Inc / W<eth	APBPI-124	Alzheimer's disease; Neurodegenerative disease; Parkinson's disease; Cerebrovascular ischemia	Estrogen modulator	Neuroprotectant; Antiparkinsonian

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
28	No Development Reported	ImmunoGen Inc	Apoptosin	Neurodegenerative disease		Immunosuppressant
29	No Development Reported	Oregon Health Sciences University	Aptiganel	Neurodegenerative disease; Parkinson's disease; Cerebrovascular disease; Cerebrovascular ischemia; Brain injury	NMDA receptor antagonist, Ionotropic glutamate receptor antagonist	Neuroprotectant; Antiparkinsonian
30	Discovery	Arena Pharmaceuticals Inc	AR-139525	Neurodegenerative disease; Parkinson's disease	Unspecified GPCR antagonist	Neuroprotectant; Antiparkinsonian
31	Discontinued	Fisons plc	AR-15896; Lanicemine	Cerebral infarction; Ischemia	NMDA receptor antagonist	Neuroprotectant
32	Discovery	AstraZeneca plc	AR-A-008055	Neurotoxicity, drug-induced; Neurodegenerative disease	GABA A agonist	Neuroprotectant
33	Phase 3 Clinical	Pfizer Inc	Aricept (Donepezil) vs. a-Tocopherol	Neurodegenerative disease; Alzheimer's disease		Neuroprotectant
34	Research Tool	AstraZeneca plc	AR-R-1779	Alzheimer's disease; Neurodegenerative disease; Anxiety disorder	ACh agonist	Nootropic agent; Anxiolytic
35	No Development Reported	AstraZeneca plc	AR-R18565	Ischemia	Calcium channel blocker	Vasodilatory agent
36	No Development Reported	Array BioPharma Inc	ARRY-142886	Neurodegenerative disease	Protein kinase inhibitor; Mek protein kinase inhibitor	Neuroprotectant
37	Discovery	AlphaRx Inc	ARX-2000; -2001; -2002; AlphaRx	Inflammation; Neurodegenerative disease; Immune deficiency	Immunomodulators	Immunostimulant
38	Discovery	Serono SA	AS-600292; AS-004509; AS-601245	Chronic obstructive pulmonary disease; Inflammation; Inflammatory bowel disease; Multiple sclerosis; Neurodegenerative disease; Rheumatoid arthritis; Asthma; Central nervous system disease; Ischemia	Jun N terminal kinase modulator; Jun N terminal kinase-2 inhibitor; Jun N terminal kinase-3a inhibitor	Vasoprotectant; Anti-inflammatory
39	Discovery	Pharmexa A/S	AutoVac	Neurodegenerative disease	Neurodegenerative Vaccine	Neuroprotectant
40	No Development Reported	Regeneron Pharmaceuticals Inc	Axokine	Huntington's chorea; Motor neurone disease; Neurodegenerative disease	CNTF agonist	Metabolic modulator

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
41	No Development Reported	Asahi Kasei Corp	AZ-36041	Alzheimer's disease; Neurodegenerative disease	Reduction of amyloid beta	Neuroprotectant
42	Discovery	BioAxone Therapeutique Inc	BA-1016	Neurodegenerative disease; Cerebrovascular ischemia; Cancer	Rho kinase inhibitor	Anticancer; Neuroprotectant
43	No Development Reported	Bayer AG	BAY-X-9227	Neurodegenerative disease	Potassium channel activator	Neuroprotectant
44	No Development Reported	Russian Academy Medical Science	BD-1054	Alzheimer's disease; Neurodegenerative disease		Nootropic agent
45	Discontinued	Sankyo Co Ltd	BGC-20-1178	Neurodegenerative disease	Beta amyloid modulator	Nootropic agent
46	Discontinued	Boehringer Ingelheim Corp	BIMU-8	Neurodegenerative disease	5-HT4 agonist	Analgesic
47	Discovery	Boston Life Sciences Inc	BLS-602; BLS-605	Neurodegenerative disease; Parkinson's disease		Neuroprotectant; Antiparkinsonian
48	Discontinued	Bristol-Myers Squibb Co	BMS-181100	Schizophrenia, Psychosis	Sigma opioid antagonist, 5-HT 1a agonist	Antipsychotic
49	Discontinued	Bristol-Myers Squibb Co	Brasofensine	Parkinson's disease	Dopamine uptake inhibitor	Antiparkinsonian
50	No Development Reported	Pharm-Eco Laboratories Inc	Breflate	Neurodegenerative disease	Brefeldin A prodrug	Nootropic agent
51	Discovery	National Institutes of Health	BTG-A derivatives	Neurodegenerative disease	Nicotinic ACh modulator; Muscarinic ACh modulator	Nootropic agent
52	No Development Reported	Roche	C60 Fullerenes	Neurodegenerative disease; Cerebrovascular ischemia; Head injury	Free radical scavenger	Neuroprotectant
53	No Development Reported	Aventis	CAS-493; Aloracetam	Alzheimer's disease		Nootropic agent
54	Phase 3 Clinical	Pfizer/Pharmacia; NIA	Celecoxib	Alzheimer's disease	Immunomodulator	Neuroprotectant; Anti-inflammatory
55	Phase 3 Clinical	Cephalon	CEP-1347	Parkinson's Disease	MAP kinase inhibitor	Neuroprotectant
56	Discovery	Cephalon Inc	CEP-3122	Alzheimer's disease; Neurodegenerative disease; Cerebrovascular ischemia	Calpain inhibitor	Neuroprotectant; Nootropic agent
57	Discovery	Cephalon Inc	CEP-4143	Neurodegenerative disease	Calpain inhibitor	Neuroprotectant
58	Discontinued	LEO Pharma A/S	CEP-4186	Alzheimer's disease; Acute myelogenous leukemia; Neurodegenerative disease; Carcinoma	Vitamin D3 agonist	Anticancer; Neuroprotectant

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
59	Discontinued	Cephalon Inc	CEP-751	Neurodegenerative disease; Prostate tumor	NGF antagonist; Protein tyrosine kinase inhibitor	Anticancer
60	Discontinued	Stem Cells Inc	CERE-20	Parkinson's disease	Growth factor agonist; Adeno-associated virus based gene therapy	Antiparkinsonian
61	Discontinued	Novartis AG	CGP-35348	Epilepsy; Neurodegenerative disease	GABA B antagonist	Anticonvulsant agent
62	Phase 1 Clinical	Chiesi Farmaceutici SpA	CHF-2060	Neurodegenerative disease; Cognitive disorder; Senile dementia	Acetylcholinesterase inhibitor	Neuroprotectant
63	Discovery	Cogent Neuroscience Inc	CNIC-568	Neurodegenerative disease; Cerebrovascular ischemia	Unspecified vector based gene therapy	Neuroprotectant
64	Discontinued	CeNeS Pharmaceuticals Inc	CNS-1044	Neurodegenerative disease; Cerebrovascular ischemia	NMDA receptor antagonist	Neuroprotectant
65	No Development Reported	CeNeS Pharmaceuticals Inc	CNS-2103	Neurodegenerative disease	Calcium channel blocker	Neuroprotectant
66	No Development Reported	CeNeS Pharmaceuticals Inc	CNS-5065	Neurodegenerative disease	NMDA receptor antagonist	Neuroprotectant
67	Discontinued	Ryan Pharmaceuticals Inc	Coenzyme Q10	Cerebrovascular ischemia	Apoptosis inhibitor	Neuroprotectant
68	No Development Reported	Pfizer Inc	CP-132484	Neurodegenerative disease	5-HT 2 agonist	Neuroprotectant
69	No Development Reported	Pfizer Inc	CP-283097	Neurodegenerative disease	NMDA receptor antagonist	Neuroprotectant
70	Discovery	Questcor Pharmaceuticals Inc	CPC-304	Neurodegenerative disease; Alzheimer's disease; Cerebrovascular ischemia	Calcium channel blocker	Neuroprotectant
71	Phase 2 Clinical	Cortex Pharmaceuticals Inc	CX-516	Cognitive disorder; Alzheimer's disease	Ampa receptor modulator	Neuroprotectant
72	Phase 1 Clinical	NIMH	Cyclophosphamide	Alzheimer's disease; Neurodegenerative disease	Immunomodulator	Neuroprotectant; Anti-inflammatory
73	Discovery	Maas Biolab LLC	Cyclosporin A	Alzheimer's disease; Parkinson's disease; ALS; Huntington's disease	Immunomodulator	Neuroprotectant; Anti-inflammatory
74	Discontinued	Servier	Dabelotine	Alzheimer's disease; Dementia	Adrenoceptor agonist; Vasopressin agonist	Nootropic agent
75	Research Tool	Suntory Ltd	DCG-IV	Neurodegenerative disease	Glutamate receptor agonist	Neuroprotectant
76	Discovery	DiverDrugsSL	DD-20207	Alzheimer's disease; Parkinson's disease	NMDA receptor modulator	Analgesic, Antiparkinsonian

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
77	Discovery	Memorial Sloan-Kettering Cancer Center	Dehydroascorbic acid	Alzheimer's disease; Neurodegenerative disease; Parkinson's disease; Cerebrovascular ischemia	Antioxidant agent	Neuroprotectant; Anti-inflammatory
78	Discontinued	Hebrew University	Dexanabinol	Cognitive disorder, Brain injury	NMDA receptor antagonist	Neuroprotectant
79	Phase 1 Clinical	Pierre Fabre SA	Dexefaroxan	Alzheimer's disease	Imidazoline receptor antagonist, Alpha 2 adrenoceptor antagonist	
80	Discovery	Schering AG	Dihydro-quinolines	Neurodegenerative disease	NO synthesis inhibitor	Neuroprotectant
81	No Development Reported	SIR International	Diperdipine	Neurodegenerative disease; Cerebral infarction; Cerebrovascular disease; Cerebrovascular ischemia	Calcium channel blocker	Antihypertensive
82	Research Tool	Merck & Co Inc	Dizocilpine	Epilepsy; Neurodegenerative disease; Cognitive disorder	NMDA receptor antagonist; Ionotropic glutamate receptor antagonist	Anticonvulsant agent
83	Discontinued	Bristol-Myers Squibb Co	DMP-543	Alzheimer's disease	Potassium channel blocker	Neuroprotectant
84	Discovery	D-Pharm Ltd	DP-103	Nervous system inflammation		Anti-inflammatory
85	Discovery	D-Pharm Ltd	DP-109	Neurodegenerative disease	Chelating agent; Apoptosis modulator	Neuroprotectant
86	Discovery	D-Pharm Ltd	DP-b99	Cerebrovascular ischemia, Epilepsy	Chelating agent, Calcium metabolism modulator	Neuroprotectant, Anticonvulsant agent
87	Discontinued	Mitsubishi-Tokyo Pharmaceuticals Inc	DPP-225	Alzheimer's disease	5-HT antagonist	Neuroprotectant
88	Discovery	Korea Research Institute of Bioscience and Biotechnology	Dykellie acid	Immune disorder; Neurodegenerative disease; Cancer	Apoptosis inhibitor	Anticancer; Anti-apoptotic
89	Phase 1 Clinical	Eisai Co Ltd	E-2101	Neurodegenerative disease; Muscle hypertonia	5-HT 2 antagonist; 5-HT 1a antagonist	Centrally-acting muscle relaxant
90	Discontinued	BTG International Ltd; Novartis	EAA-404; Midafotel	Epilepsy; Neurodegenerative disease; Cerebrovascular ischemia; Head injury	NMDA receptor antagonist	Neuroprotectant
91	Discovery	Wyeth Research	EAB-318	Epilepsy; Neurodegenerative disease; Cerebrovascular ischemia	NMDA receptor antagonist	Neuroprotectant; Anticonvulsant agent
92	Discontinued	Mitsubishi-Tokyo Pharmaceuticals Inc	Edaravone	Cerebrovascular ischemia	Free radical scavenger	Neuroprotectant

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
93	Discovery	Universidad Complutense de Madrid	EF-7412	Neurodegenerative disease; Anxiety disorder; Depression		Antidepressant; Anxiolytic
94	No Development Reported	EGIS Gyogyszergyar RT	EGIS-7444	Alzheimer's disease; Neurodegenerative disease	NMDA receptor antagonist	Neuroprotectant
95	Phase 1 Clinical	ExonHit Therapeutics SA	EHT-202	Neurodegenerative disease		Neuroprotectant
96	Discontinued	Synthelabo	Eliprodil	Motor neurone disease; Neurodegenerative disease; Cerebrovascular disease; Cerebrovascular ischemia; Head injury	NMDA receptor antagonist	Neuroprotectant
97	Discontinued	Knoll GmbH	Emopamil	Migraine; Neurodegenerative disease; Cerebrovascular ischemia	5-HT 2 antagonist; 5-HT antagonist; Calcium channel blocker	Neuroprotectant; Vasodilatory agent
98	Discovery	University of Tennessee Memphis	EP-475	Neurodegenerative disease	Calpain inhibitor	Neuroprotectant
99	Phase 2 Clinical	ASAC Pharmaceutical International AIE	EQA-00; Anapsos	Multiple sclerosis	not specified	Immunomodulator, Nootropica agent
100	Phase 3 Clinical	ASAC Pharmaceutical International AIE	EQA-00; Anapsos	Alzheimer's disease	not specified	Immunomodulator, Nootropica agent
101	No Development Reported	Kyowa Hakko Kogyo Co Ltd	ES-242-1	Neurodegenerative disease	NMDA receptor antagonist	Neuroprotectant
102	Phase 3 Clinical	NIA (National Institute of Aging)	Estrogen or Estrogen/ Progesterone	Alzheimer's Disease	Immunomodulator	Neuroprotectant; Anti-inflammatory
103	No Development Reported	GD Searle & Co	Ethanoanthracene derivatives	Neurodegenerative disease	Sigma opioid antagonist	Neuroprotectant
104	No Development Reported	Centre de Recherche Pierre Fabre	F-10981	Alzheimer's disease; Neurodegenerative disease; Parkinson's disease	Alpha 2 adrenoceptor antagonist	Antiparkinsonian
105	Discovery	Tokyo Metropolitan Institute	F-2-CCG-I	Epilepsy; Neurodegenerative disease; Head injury	Metabotropic glutamate receptor modulator	Anticonvulsant agent
106	No Development Reported	Pharmacia & Upjohn Inc	FCE-29484A	Neurodegenerative disease; Parkinson's disease; Epilepsy		Antiparkinsonian; Anticonvulsant agent
107	No Development Reported	Pharmacia & Upjohn Inc	FCE-29642A	Neurodegenerative disease; Parkinson's disease; Epilepsy		Antiparkinsonian; Anticonvulsant agent
108	No Development Reported	Amgen Inc	FGF-9; rhuFGF-16	Multiple Sclerosis; Neurodegenerative disease	FGF-9 agonist; FGF-16 agonist	Neuroprotectant

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
109	No Development Reported	Amgen Inc	Fibroblast growth factor, ersofermin	Multiple sclerosis; Neurodegenerative disease; Cerebrovascular ischemia	FGF-2 agonist	Neuroprotectant
110	No Development Reported	Kirin Brewery Co Ltd	Formobactin	Neurodegenerative disease; Cerebrovascular ischemia		Neuroprotectant
111	No Development Reported	Fisons plc	FPL-16283	Neurodegenerative disease	NMDA receptor antagonist	Neuroprotectant
112	No Development Reported	Neurochem Inc	GAG mimetics	Alzheimer's disease	Amyloid protein deposition inhibitor	Neuroprotectant
113	Discovery	Synaptica Ltd	Galantamine derivatives	Alzheimer's disease	Acetylcholinesterase inhibitor	Neuroprotectant
114	No Development Reported	GlaxoSmithKline plc	Galdansetron	Neurodegenerative disease	5-HT 3 antagonist	Neuroprotectant
115	Phase 2 Clinical	Chiesi Farmaceutici SpA	Ganstigmine	Alzheimer's disease; Neurodegenerative disease; Cognitive disorder	Acetylcholinesterase inhibitor	Neuroprotectant
116	Discontinued	GlaxoSmithKline plc	Gavestinel	Neurodegenerative disease; Cerebrovascular ischemia	Glycine antagonist	Neuroprotectant
117	Discovery	Genentech Inc	GDNF	Neurodegenerative disease; Parkinson's disease	Unspecific growth factor agonist	Antiparkinsonian
118	Phase 2 Clinical	Amgen Inc	GDNF; Liatermine	Motor neurone disease; Neurodegenerative disease; Parkinson's disease	Unspecified growth factor agonist	Antiparkinsonian
119	Discovery	CeNeS Pharmaceuticals Inc, Acorda	GGF-2	Multiple sclerosis, Myasthenia gravis	NGF agonist	Neuroprotectant
120	Phase 2 Clinical	ViatraVIATRIS GmbH	GKE-841; Retigabine	Epilepsy	GABA A agonist; Potassium channel activator	Anticonvulsant agent
121	No Development Reported	Allelix Neuroscience Inc	Glialines, Throphix	Alzheimer's disease; Huntington's chorea; Parkinson's disease	Cell therapy; Glial neurotrophic factors	Neuroprotectant; Antiparkinsonian
122	Enrollment	NINDS (National Institute of Neurological Disorders and Stroke)	GM-1 ganglioside	Neurodegenerative disease		Neuroprotectant
123	Phase 2 Clinical	Fidia Farmaceutici	GM-1 ganglioside	Parkinson's disease	Ionotropic glutamate receptor agonist	Neuroprotectant
124	No Development Reported	SICOR Inc	GP-14683	Epilepsy; Angina; Neurodegenerative disease	ARA-100 prodrug	Vasodilatory agent; Anticonvulsant agent
125	Discontinued	Guilford Pharmaceuticals Inc	GPI-1337	Neurodegenerative disease; Parkinson's disease		Neuroprotectant; Antiparkinsonian

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
126	Discontinued	Guilford Pharmaceuticals Inc	GPI-1485	Parkinson's disease	Neuroimmunophilin	Antiparkinsonian
127	Research Tool	GlaxoSmithKline plc	GR-73632	Neurodegenerative disease	NK1 agonist	Neuroprotectant
128	Discontinued	GlaxoSmithKline plc	GR-89696	Neurodegenerative disease	Kappa opioid agonist	Neuroprotectant
129	Discovery	AstraZeneca plc	GSK-3 inhibitors	Alzheimer's disease	Glycogen synthase kinase family inhibitor	Neuroprotectant
130	Discontinued	Gliatech Inc	GT-2342	Neurodegenerative disease		
131	Discovery	GBtherapeutics Ltd	GT-715	Neurodegenerative disease	NO modulator	Neuroprotectant
132	Discovery	BTG International Ltd	GV-2400	Neurodegenerative disease; Cardiovascular disease; Cancer	HSV gene therapy	Neuroprotectant
133	Discontinued	EGIS Gyogyszergyar RT	GYKI-52466	Alzheimer's disease; Parkinson's disease; Epilepsy	AMPA receptor agonist	Anticonvulsant agent, Antiparkinsonian
134	No Development Reported	American Cyanamid Co	HBNF	Hematological disease; Neurodegenerative disease	Heparin binding neurotrophic factor; FGF-8 agonist, Peptide	
135	Discovery	Hunter-Fleming Ltd	HF-0220	Cerebrovascular ischemia		Neuroprotectant
136	Phase 1 Clinical	Aventis	HP-184	Spinal chord injury	Ion channel modulator, Acetylcholine release stimulator	Neuroprotectant
137	Discovery	Aegera Therapeutics Inc	IAP	Parkinson's disease, Multiple sclerosis, Cerebrovascular ischemia	Anti-apoptotic gene therapy	Neuroprotectant
138	Discovery	Idun Pharmaceuticals Inc	IDN-6556	Neurodegenerative disease	Caspase inhibitor	Apoptosis inhibitor; Anti-inflammatory
139	Discovery	Neurocrine Biosciences Inc	IGF modulators, Neurocrine	Neurodegenerative disease; Central nervous system disease; Cerebrovascular ischemia	Insulin-like growth factor 1 agonist	Neuroprotectant; Antipsychotic
140	Discontinued	Pfizer Inc	Igmesine	Alzheimer's disease	Sigma opioid agonist	Neuroprotectant
141	No Development Reported	Ortho Pharmaceutical Corp	Imidazole derivatives	Pain; Neurodegenerative disease	Alpha 3 adrenoceptor agonist	Analgesic
142	Discovery	Servier	Imidazolyl nitrones	Nervous system injury; Neurodegenerative disease	Free radical scavenger	Neuroprotectant; Antioxidant agent
143	Discovery	Boston Life Sciences Inc	Inosine, BLSI	Neurodegenerative disease		Neuroprotectant
144	Phase 1 - 2 Clinical	NCCR	Interferon Alpha	Alzheimer's disease; Dementia	Immunomodulator	Neuroprotectant; Anti-inflammatory
145	No Development Reported	Yeda Research & Development Co Ltd	Interleukin-2-like growth factor	Neurodegenerative disease	IL-2 agonist	Growth factor agonist

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
146	Phase 3 Clinical	Research Triangle Institute	Iometopane	Parkinson's disease	Dopamine uptake inhibitor; SPECT contrast agent	Neuroprotectant; Antiparkinsonian
147	Phase 2 Clinical	Nippon Chemiphar Co Ltd	Ipenoxazone	Alzheimer's disease; Neurodegenerative disease; Middle ear disease	NMDA receptor antagonist; Ionotropic glutamate receptor antagonist	Smooth muscle relaxant
148	Discovery	Chronogen Inc	isp-1; clk-1	Neurodegenerative disease	Gene expression regulation	Neuroprotectant
149	No Development Reported	Aventis	Itameline	Dementia, Alzheimer's disease, Cognitive disorder	Muscarinic ACh agonist	Nootropic agent
150	No Development Reported	Kyowa Hakko Kogyo Co Ltd	KF-17329	Neurodegenerative disease; Cerebrovascular ischemia		Neuroprotectant
151	Discovery	Krenitsky Pharmaceuticals Inc	KP-102	Neurodegenerative disease	NGF agonist	Neurotrophic agent
152	Discovery	Keryx Biopharmaceuticals Inc	KRX-411	Neurodegenerative disease	Protein kinase modulator	Neuroprotectant
153	Phase 2 Clinical	Kyowa Hakko	KW-6002; Istradefylline	Parkinson's disease; Major depressive disorder	Adenosine A2a antagonist	Neuroprotectant
154	No Development Reported	Merck & Co Inc	L-687306	Alzheimer's disease	Muscarinic M1 agonist	Nootropic agent
155	Research Tool	Merck & Co Inc	L-687414	Epilepsy; Neurodegenerative disease	NMDA receptor antagonist	Anticonvulsant agent
156	Research Tool	Merck & Co Inc	L-689560	Neurodegenerative disease	NMDA receptor antagonist	Anticonvulsant agent
157	No Development Reported	Merck & Co Inc	L-701252	Alzheimer's disease; Epilepsy; Cerebrovascular ischemia	NMDA receptor antagonist	Neuroprotectant; Anti-convulsant agent
158	Phase 3 Clinical	GlaxoSmithKline plc	Lamotrigine	Neuropathy	Glutamate release inhibitor	Neuroprotectant; Anticonvulsant agent
159	Discovery	Louisiana University	LAU-0501	Alzheimer's disease; Parkinson's disease	Cyclooxygenase 2 inhibitor	Anti-inflammatory; Antiparkinsonian
160	Discontinued	Roche	Lazabemide	Alzheimer's disease; Neurodegenerative disease; Parkinson's disease; Dementia	MAO B inhibitor	Antiparkinsonian
161	Phase 2 Clinical	Spectrum Pharmaceuticals	Leteprinim	Parkinson's disease; Spinal chord injury	FGF agonist; NGF agonist	Nootropic agent; Antiparkinsonian
162	Discovery	Fidia-Georgetown Institute for Neurosciences	LIGA-20	Neurodegenerative disease; Cerebrovascular ischemia		Neuroprotectant
163	No Development Reported	Eli Lilly & Co	LY-178002	Inflammation; Neurodegenerative disease	Antioxidant agent	Anti-inflammatory; Immunosuppressant
164	No Development Reported	Eli Lilly & Co	LY-233536	Neurodegenerative disease	Competitive NMDA antagonist	Antiparkinsonian; Anticonvulsant agent

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
165	No Development Reported	Eli Lilly & Co	LY-235959	Neurodegenerative disease	Competitive NMDA antagonist	Antiparkinsonian; Anticonvulsant agent
166	Discontinued	Eli Lilly & Co	LY-274614	Epilepsy; Alzheimer's disease; Neurodegenerative disease; Opiate use disorder; Parkinson's disease; Dementia	NMDA receptor antagonist	Antiparkinsonian; Anticonvulsant agent
167	No Development Reported	Eli Lilly & Co	LY-302427	Neurodegenerative disease	Metabotropic glutamate receptor modulator	Neuroprotectant
168	No Development Reported	Eli Lilly & Co	LY-354006	Alzheimer's disease; Neurodegenerative disease	Muscarinic ACh modulator	Nootropic agent
169	Phase 2 Clinical	Eli Lilly & Co	LY-354740	Anxiety disorder	Metabotropic glutamate receptor 2 agonist	Anxiolytic; Anticonvulsant agent
170	Phase 1 Clinical	Eli Lilly & Co	LY-451395	Alzheimer's disease; Neurodegenerative disease	AMPA receptor agonist	Neuroprotectant
171	Discovery	Mitsubishi-Tokyo Pharmaceuticals Inc	MCC-257	Diabetic neuropathy; Neurodegenerative disease	NGF agonist	Neuroprotectant
172	Discontinued	Mitsubishi-Tokyo Pharmaceuticals Inc	MCI-225	Alzheimer's disease; Neurodegenerative disease; Depression	5-HT 3 antagonist; Norepinephrine uptake inhibitor	Antidepressant; Metabolic activator
173	No Development Reported	Hoechst Marion Roussel Inc	MDL-100748	Epilepsy; Neurodegenerative disease	NMDA/Glycine antagonist; Glycine antagonist	Anticonvulsant agent
174	Discontinued	Hoechst Marion Roussel Inc	MDL-101002	Neurodegenerative disease; Cerebrovascular ischemia; Septic shock	Free radical scavenger	Neuroprotectant; Antioxidant agent
175	No Development Reported	Hoechst Marion Roussel Inc	MDL-102288	Neurodegenerative disease	Glycine antagonist	Neuroprotectant
176	No Development Reported	Hoechst Marion Roussel Inc	MDL-105519	Neurodegenerative disease	Glycine antagonist; NMDA receptor antagonist	Neuroprotectant
177	No Development Reported	Hoechst Marion Roussel Inc	MDL-27266	Epilepsy; Neurodegenerative disease	Glycine antagonist; NMDA receptor antagonist	Iontropic glutamate receptor antagonist; Anticonvulsant agent
178	Discontinued	Hoechst Marion Roussel Inc	MDL-28170	Alzheimer's disease; Neurodegenerative disease	Cysteine protease inhibitor; Hydrolase inhibitor; Amyloid protein deposition inhibitor; Calpain inhibitor	Antiparasitic; Neuroprotectant
179	No Development Reported	Hoechst Marion Roussel Inc	MDL-29951	Epilepsy; Neurodegenerative disease	NMDA/Glycine antagonist	Anticonvulsant agent

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
180	Discontinued	Cephalon Inc; Chiron	Mecasermin	Diabetic neuropathy; Motor neurone disease; Neurodegenerative disease	Insulin-like growth factor 1 agonist	Neuroprotectant
181	Phase 1 Clinical	Bayer AG / Memory Pharmaceuticals Corp	MEM-1003	Dementia, Alzheimer's Disease, Cognitive disorder	Calcium channel modulator	Neuroprotectant
182	Phase 3 Clinical	Merz/Forrest	Memantine	Neurodegenerative disease	NMDA receptor antagonist	Neuroprotectant; Analgesic
183	Discontinued	Pharmed Dr Liedtke GmbH	Mepindolol	Neurodegenerative disease	Beta adrenoceptor antagonist	Antihypertensive
184	Discovery	Pharmacyclics Inc	Metallohexaphyrins	Neurodegenerative disease; Motor neurone disease; ALS	Chelating agent	Neuroprotectant
185	Discovery	Sibia Neuroscience; Novartis AG	Methylphenyle thynylpyridine (MPEP)	Epilepsy; Pain; Neurodegenerative disease; Anxiety disorder; Cerebrovascular ischemia; Head injury	Metabotropic glutamate receptor 5 antagonist; NMDA receptor antagonist; AMPA receptor antagonist	Neuroprotectant; Analgesic; Anticonvulsant agent
186	Discovery	Mera Pharmaceuticals Inc	Microalgal compound	Age related macular degeneration; Hypercholesterolemia; Neurodegenerative disease; Cancer		Anticancer; Antihypercholesterolemic agent
187	Discontinued	GD Searle & Co	Milacemide	Epilepsy; Alzheimer's disease; Neurodegenerative disease; Dementia; Depression	MAO B inhibitor; NMDA receptor agonist; Oxidoreductase inhibitor	Antidepressant; Anticonvulsant agent
188	Phase 3 Clinical	Pharmacia/Boehringer	Mirapex (pramipexole);	Alzheimer's disease	prevention of autooxidation of dopamine	Neuroprotectant
189	Discontinued	PAION GmbH	MLN-519	Nervous system inflammation	Proteasome inhibitor	Neuroprotectant; Anti-inflammatory
190	No Development Reported	Mitsui Pharmaceuticals Inc	MS-153	Cerebrovascular ischemia	Glutamate receptor modulator	Neuroprotectant
191	No Development Reported	Taisho Pharmaceutical Co Ltd	MT-5	Neurodegenerative disease	Neuronal growth factor receptor agonist	
192	No Development Reported	Nisshin Flour Milling Co Ltd	N-3393	Neurodegenerative disease; Cerebrovascular ischemia		Vasodilatory agent
193	Discovery	Toray Industries Inc	Naltrindole derivatives	Neurodegenerative disease	Delta opioid antagonist	Neuroprotectant
194	Discovery	National Institutes of Health	NAPVSIPQ	Neurodegenerative disease	Antioxidant agent	Neuroprotectant
195	Discovery	Neurocrine Biosciences Inc	NBI-30702	Cerebrovascular ischemia	ACTH releasing factor antagonist	Neuroprotectant
196	Phase 2 Clinical	Neurochem Inc	NC-531	Alzheimer's disease	Amyloid protein deposition inhibitor	Neuroprotectant

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
197	Phase 2 - 3 Clinical	Neotherapeutics	Neotrofin	Neurodegenerative disease	Immunomodulator	Neuroregeneration
198	Phase 2 Clinical	Merz & Co GmbH	Neramexane	Central nervous system disease		Neuroprotectant; Analgesic; Antiparkinsonian
199	Phase 1 Clinical	Tuszynski Lab, UCSD	Nerve growth factor gene therapy	18-month trial to determine whether therapy prevents cell loss in AD. Involves surgical implant.	Nerve growth factor gene therapy	Neuroprotectant
200	Discovery	NsGene A/S	Neublastin	Neurodegenerative disease	Neuronal growth factor	Neuroprotectant
201	Discontinued	Apollo Biopharmaceutics Inc	Neurocalc	Alzheimer's disease; Neurodegenerative disease	Calcium metabolism modulator	Neuroprotectant
202	No Development Reported	Neurocal International Inc	Neurostrol	Alzheimer's disease; Neurodegenerative disease	Antioxidant agent	Neuroprotectant
203	Discontinued	AstraZeneca plc	NLA-715; Clomethiazole; Zendra	Epilepsy; Cerebrovascular ischemia, Parkinson's disease, Epilepsy, Alzheimer's disease	GABA A agonist	Neuroprotectant, Anticonvulsant agent
204	No Development Reported	Novo Nordisk A/S	NNC-07-0775	Cerebrovascular ischemia,; Epilepsy	Metabotropic glutamate receptor 1 antagonist, Ionotropic glutamate receptor antagonist	Neuroprotectant
205	Discontinued	Novo Nordisk A/S	NNC-07-9202	Epilepsy; Neurodegenerative disease; Psychosis; Cerebrovascular ischemia	Neuroprotectant; NMDA receptor antagonist; Ampa receptor antagonist	Neuroprotectant; Antipsychotic; Anticonvulsant agent
206	No Development Reported	Regeneron Pharmaceuticals Inc	Noggin	Neurodegenerative disease	Growth factor agonist	Neuroprotectant
207	No Development Reported	Hedral Therapeutics Inc	Norleu	Neurodegenerative disease; Cerebrovascular ischemia	angiokine	Vasodilatory agent
208	Phase 1 Clinical	Medinox Inc	NOX-700	Neurodegenerative disease	NO modulator	Antioxidant agent
209	Discovery	NPS Pharmaceuticals Inc	NPS-1407	Epilepsy; Pain; Neurodegenerative disease; Cerebrovascular ischemia; Depression	NMDA receptor antagonist	Antidepressant; Analgesic; Anticonvulsant agent
210	Discontinued	NPS Pharmaceuticals Inc	NPS-846	Epilepsy; Pain; Neurodegenerative disease; Cerebrovascular ischemia	Ionotropic glutamate receptor antagonist	Neuroprotectant; Anticonvulsant agent
211	Discovery	Centaur Pharmaceuticals Inc	NRT-115	Multiple sclerosis, Inflammation	Cytokine release modulator	Anti-inflammatory

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
212	Discontinued	NeuroSearch AS	NS-1209	Neurodegenerative disease; Cerebrovascular ischemia	AMPA receptor antagonist	Neuroprotectant
213	Research Tool	NeuroSearch AS	NS-1608	Cerebrovascular ischemia	Potassium channel activator	Neuroprotectant
214	Phase 2 Clinical	NeuroSearch	NS-2330	Neurodegenerative disease; Parkinson's disease	Dopamine reuptake inhibitor.	Neuroprotectant
215	Discontinued	NeuroSearch AS	NS-257	Neurodegenerative disease; Cerebrovascular ischemia	AMPA receptor antagonist	Neuroprotectant
216	Discontinued	NeuroSearch AS	NS-377	Alzheimer's disease; Neurodegenerative disease; Cognitive disorder	AMPA receptor antagonist	Neuroprotectant
217	Discontinued	NeuroSearch AS	NS-638	Neurodegenerative disease; Cerebrovascular ischemia	Calcium channel blocker	Neuroprotectant; Vasodilatory agent
218	Discontinued	NeuroSearch AS	NS-649	Alzheimer's disease; Neurodegenerative disease; Cognitive disorder	Calcium channel blocker	Neuroprotectant
219	Discovery	Nymox Pharmaceutical Corp	NXD-5150	Neurodegenerative disease		Neuroprotectant
220	Phase 3 Clinical	Centaur Pharmaceuticals Inc, Astra Zeneca plc	NXY-059	Alzheimer's disease; Multiple sclerosis; Neurodegenerative disease; Arthritis; Cerebrovascular ischemia	Free radical scavenger; NO synthesis inhibitor	Neuroprotectant
221	Discontinued	Novo Nordisk A/S	Odapipam	Neurodegenerative disease; Psychosis; Schizophrenia	Dopamine D1 antagonist	Antipsychotic
222	Phase 2 Clinical	Lilly	Olanzapine	Alzheimer's disease	5-HT2 receptor antagonist; Dopamine D2 receptor antagonist	Antipsychotic
223	Phase 1 Clinical	Ono Pharmaceutical Co Ltd	ONO-2506	Cerebrovascular Ischemia, Parkinson's Disease		Neuroprotectant; Antiparkinsonian
224	No Development Reported	Otsuka Pharmaceuticals Co Ltd	OPC-14117	Dementia, Cerebrovascular ischemia, Dementia, Huntington's chorea	Free radical scavenger	Neuroprotectant; Antiparkinsonian
225	Phase 2 Clinical	Phytopharm plc	P-58	Dementia; Alzheimer's disease; Parkinson's disease	Muscarinic M1 modulator	Neuroprotectant; Nootropic agent
226	No Development Reported	Aventis	P-9939	Neurodegenerative disease	Glycine partial agonist	

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
227	Phase 1 Clinical	Tulane University	PACAP	Neurodegenerative disease; Cerebrovascular ischemia	Pituitary adenylate cyclase activating polypeptide (PACAP); Adenylate cyclase stimulator	Neuroprotectant
228	Phase 3 Clinical	Lifegroup SpA	Palmidrol	Neurodegenerative disease; Inflammation	5-HT release inhibitor	Neuroprotectant; Anti-inflammatory
229	Discovery	Panacea Pharmaceuticals Inc	PAN-811	Alzheimer's disease	Antioxidant agent	Neuroprotectant
230	No Development Reported	Regeneron Pharmaceuticals Inc	Pan-Neurotrophin-1	Alzheimer's disease; Neurodegenerative disease; Psychosis	Unspecified growth factor agonist	Neuroprotectant; Antipsychotic
231	Phase 2 Clinical	Prana Biotechnology	PBT-1; Clioquinol	Alzheimer's disease	Chelating agent; Beta amyloid modulator	Neuroprotectant
232	No Development Reported	Parke-Davis & Co	PD-132026	Neurodegenerative disease	Dopamine agonist	Neuroprotectant; Antipsychotic
233	No Development Reported	Pfizer Inc	PD-150606	Neurodegenerative disease; Neuropathy	Calpain inhibitor	Neuroprotectant
234	Discovery	Pfizer Inc	PD-159265	Neurodegenerative disease	AMPA receptor antagonist	Neuroprotectant
235	No Development Reported	Parke-Davis & Co	PD-90780	Nervous system tumor; Neurodegenerative disease	NGF antagonist	Neuroprotectant
236	No Development Reported	Pharmaceutical Discovery Corp	PDC-008.004	Alzheimer's disease; Neurodegenerative disease	Muscarinic M2 agonist	Nootropic agent
237	Discovery	INSERM	PE21	Neurodegenerative disease; Parkinson's disease	Dopamine uptake inhibitor	Antiparkinsonian
238	Discovery	Axonyx Inc	Phenserine	Alzheimer's disease	Acetylcholinesterase inhibitor	Anti-amyloidogenic
239	Discovery	University of Nottingham	Philanthotoxins	Neurodegenerative disease; Cognitive disorder	Nicotinic ACh antagonist; AMPA receptor antagonist	Nootropic agent
240	Discovery	Pierre Fabre SA	Piperidine derivatives	Alzheimer's disease; Neurodegenerative disease; Parkinson's disease	Alpha 1 adrenoceptor antagonist; Alpha 2 adrenoceptor antagonist	Antiparkinsonian
241	Discovery	Universita di Siena	PK-11195 analogs	Neurodegenerative disease; Anxiety disorder	Dopamine D2 antagonist; 5-HT 1a antagonist; Glutamate release inhibitor	Anxiolytic; Imaging agent; BDZ agonist
242	Discovery	Proneuron Biotechnologies Inc	PN-277	Neurodegenerative disease		Neuroprotectant; Immunomodulator
243	No Development Reported	Pharmacia & Upjohn Inc	PNU-101033E	Neurodegenerative disease; Ischemia		Neuroprotectant; Antioxidant agent
244	No Development Reported	Pharmacia & Upjohn Inc	PNU-157678	Neurodegenerative disease	Unclassified enzyme inhibitor	Neuroprotectant

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
245	Discontinued	Pharmacia & Upjohn Inc	PNU-87663	Neurodegenerative disease	Coagulation inhibitor; Antithrombin III	Antioxidant agent
246	Discovery	Polifarma SpA	POL-255	Diabetic neuropathy; Neurodegenerative disease; Schizophrenia	Dopamine agonist	Antipsychotic
247	Discontinued	Gedeon Richter Ltd	Posatirelin	Neurodegenerative disease	TRH agonist	Neuroprotectant
248	No Development Reported	Pracis Pharmaceuticals Inc	PPI-368	Alzheimer's disease; Neurodegenerative disease	Amyloid protein deposition inhibitor	Neuroprotectant
249	Discovery	Prescient NeuroPharma Inc	PRE-103	Neurodegenerative disease; Anxiety disorder; Ischemia	Metabotropic glutamate receptor agonist	Neuroprotectant; Anxiolytic
250	Discontinued	Aventis	Propentofylline	Alzheimer's disease, Dementia	Phosphodiesterase inhibitor	
251	Discontinued	Takeda Chemical Industries Ltd	Protirelin	Alzheimer's disease; Neurodegenerative disease; Dementia	TRH agonist	Nootropic agent
252	Discovery	Pharmos Corp	PRS-211220	Multiple sclerosis; Neurodegenerative disease; Parkinson's disease; Cerebrovascular ischemia; Nervous system inflammation; Brain injury	Cyclooxygenase 2 inhibitor; Chemokine antagonist; NMDA receptor antagonist; Cannabinoid agonist; Cytokine modulator	Neuroprotectant; Analgesic; Antiparkinsonian; Non-steroidal anti-inflammatory
253	Phase 2 Clinical	Phytopharm plc	PYM-50028	Neurodegenerative disease	Dopamine modulator	Neuroprotectant; Nootropic agent
254	Discovery	Quark Biotech Inc	QG-2283	Neurodegenerative disease		Neuroprotectant
255	Phase 3 Clinical	Teva Pharmaceutical Industries Ltd	Rasagiline	Alzheimer's disease; Neurodegenerative disease; Parkinson's disease	Apoptosis inhibitor; MAO B inhibitor	Antiparkinsonian
256	Discontinued	Centaur Pharmaceuticals Inc	REN-1654	Alzheimer's disease, Multiple sclerosis		Neuroprotectant, Antiparkinsonian
257	Discovery	ReNeuron (UK) Ltd	ReN-1820	Alzheimer's disease; Inflammation; Pain; Neurodegenerative disease; Dementia	NGF antagonist	Nootropic agent; Analgesic; Anti-inflammatory
258	Discovery	Rinat Neuroscience Corp	RI-820	Motor neurone disease; Spinal muscular atrophy	Protein based therapeutic	Neuroprotectant
259	Phase 3 Clinical	Aventis	Rilutek (Riluzole) + Dopamine agonist	Parkinson's disease	Protein kinase C inhibitor, Sodium channel blocker, glutamate release inhibitor	Neuroprotectant
260	No Development Reported	R J Reynolds Tobacco Co	RJR-1401	Alzheimer's disease; Neurodegenerative disease	Nicotinic ACh agonist	Nootropic agent

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
261	No Development Reported	Roche	Ro-09-2210	Neurodegenerative disease; Autoimmune disease	MAP kinase inhibitor	Immunomodulator
262	Discontinued	Schering AG	Rolipram	HIV infection; Multiple sclerosis; Neurodegenerative disease; Asthma; Tardive dyskinesia; Depression	PDE 4 inhibitor; TNF antagonist	Nootropic agent; Antidepressant
263	No Development Reported	Rhone-Poulenc Rorer Inc	RPR-104632	Neurodegenerative disease	NMDA receptor antagonist	Neuroprotectant
264	Discovery	Roche	RS-100642	Neurodegenerative disease; Cerebrovascular ischemia	Sodium channel blocker	Neuroprotectant
265	No Development Reported	Servier	S-14820	Neurodegenerative disease; Central nervous system disease	TRH agonist	Neuroprotectant
266	Discovery	Servier	S-176251; S-34730-1; S-34730	Neurodegenerative disease; Cerebrovascular ischemia; Seizure, epilepsy & convulsion	AMPA receptor antagonist	Neuroprotectant; Anticonvulsant agent
267	Discovery	Servier	S-18986	Neurodegenerative disease; Cognitive disorder; Cerebrovascular ischemia	Glutamate receptor antagonist; AMPA receptor modulator	Neuroprotectant
268	Discontinued	Shionogi & Co Ltd	S-312-d	Neurodegenerative disease; Cerebrovascular ischemia	Calcium channel blocker	Antihypertensive; Class IV antiarrhythmic agent
269	Discovery	Servier	S-33113-1	Neurodegenerative disease; Cerebrovascular ischemia	Antioxidant agent	Neuroprotectant
270	Discontinued	Janssen Pharmaceutica	Sabeluzole	Alzheimer's disease; Dementia		Neuroprotectant
271	Phase 2 Clinical	Newron Pharmaceuticals SpA	Safinamide	Parkinson's disease; Epilepsy	Calcium channel blocker; Dopamine uptake inhibitor	Neuroprotectant; Antiparkinsonian
272	Discontinued	GlaxoSmithKline plc	SB-271046	Alzheimer's disease; Schizophrenia	5-HT antagonist	Antipsychotic
273	Discovery	GlaxoSmithKline plc	SB-277011	Schizophrenia	Dopamine D3 antagonist	Antipsychotic
274	Phase 2 Clinical	Russian Academy of Sciences	SEMAX	Alzheimer's disease; Neurodegenerative disease; Cerebrovascular ischemia	ACTH agonist	Neuroprotectant; Vasoprotectant
275	Discovery	SIBIA Neurosciences Inc	SIB-1553A	Neurological disease; Parkinson's disease	Nicotinic ACh modulator	Antiparkinsonian

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
276	Phase 2 Clinical	SIBIA Neurosciences Inc	SIB-1553A	Alzheimer's disease	Nicotinic ACh modulator	Antiparkinsonian
277	No Development Reported	SIBIA Neurosciences Inc	SIB-1765F	Alzheimer's disease	Nicotinic ACh agonist	Nootropic agent; Antiparkinsonian
278	Discovery	Schering-Plough Corp	Siclofen	Neurodegenerative disease	GABA B agonist	Neuroprotectant
279	Discovery	Senju Pharmaceutical Co Ltd	SJA-6017	Muscular dystrophy; Neurodegenerative disease; Cataract; Cerebrovascular ischemia	Cysteine protease inhibitor; Calpain inhibitor	Neuroprotectant
280	No Development Reported	GlaxoSmithKline plc	SKF-74652	Alzheimer's disease; Neurodegenerative disease	Beta amyloid generation inhibitor; Amyloid protein deposition inhibitor	Anti-amyloidogenic
281	No Development Reported	Synthelabo	SL-34.0026	Neurodegenerative disease; Parkinson's disease	MAO B inhibitor	Antiparkinsonian
282	Discontinued	Solevay SA	SLV-308	Parkinson's disease	Dopamine D2 agonist; Adrenoceptor agonist; 5-HT 1a agonist	Neuroprotectant; Antiparkinsonian
283	No Development Reported	Elan Pharmaceuticals Inc	SNX-482	Neurodegenerative disease	Calcium channel blocker	Nootropic agent
284	Discovery	Supratek Pharma Inc	SP-(V5.2)C	Neurodegenerative disease	VEGF antagonist	Anticancer; Antiarrhythmic agent
285	Discovery	Celgene Corp	SPC-9766	Neurodegenerative disease; Parkinson's disease; Ischemia; Cerebrovascular ischemia	Jun N terminal kinase inhibitor	Neuroprotectant; Antiparkinsonian
286	Discovery	Sanochemia Pharmazeutika AG	SPH-1371	Alzheimer's disease; Dementia	Cholinesterase inhibitor	Neuroprotectant
287	Discovery	Alviva Biopharmaceuticals Inc / Schwarz	SPM-914	Alzheimer's disease; Huntington's chorea; Motor neurone disease; Neurodegenerative disease; Parkinson's disease	Apoptosis inhibitor	
288	Discovery	Albert-Ludwigs-Universitaet Freiburg	SPM-935	Neurodegenerative disease		Neuroprotectant
289	Phase 1 Clinical	Sanofi-Synthelabo	SSR-180575	Nervous system injury; Neurodegenerative disease	Benzodiazepine agonist	Neuroprotectant; Nootropic agent
290	Discovery	Sanofi-Synthelabo	SSR-482073	Neurodegenerative disease	Benzodiazepine agonist	Neuroprotectant; Nootropic agent
291	Phase 3 Clinical	Pfizer Inc	Sumanriole	Parkinson's disease	Dopamine D2 agonist	Neuroprotectant, Antiparkinsonian
292	No Development Reported	Suntory Ltd	SUN-C5174	Neurodegenerative disease	5-HT 2 antagonist	Vasodilatory agent

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
293	No Development Reported	Allelix Neuroscience Inc	Survivins	Neurodegenerative disease	Modification of signal transduction of neurotrophic pathways	Neuroprotectant
294	Discovery	Annovis Inc	SYM-2207	Alzheimer's disease; Neurodegenerative disease; Cerebrovascular ischemia	AMPA receptor antagonist	Neuroprotectant
295	Phase 2 Clinical	Toyama Chemical Co Ltd	T-588	Alzheimer's disease	Protein kinase stimulator; Acetylcholine release stimulator	Neuroprotectant
296	Discontinued	American Biogenetic Sciences Inc	Tacrine analogs, ABS-301, ABS-302, ABS-304	Alzheimer's disease; Neurodegenerative disease	Acetylcholinesterase inhibitor	Neuroprotectant
297	No Development Reported	Eli Lilly & Co	Talampanel	Cerebrovascular ischemia; Motor neuron disease	AMPA receptor agonist	Neuroprotectant
298	Phase 2 Clinical	IVAX Corp	Talampanel	Epilepsy; Parkinson's disease	AMPA receptor agonist	Neuroprotectant
299	Phase 3 Clinical	Tanabe Seiyaku Co Ltd	Taltirelin	Alzheimer's disease; Dementia	TRH agonist; Dopamine modulator	TRH agonist
300	Discontinued	Takeda Chemical Industries Ltd	TAN-950A	Neurodegenerative disease	Ionotropic glutamate receptor agonist; NMDA receptor agonist	Neuroprotectant
301	Discovery	Targacept Inc	TC-2559	Neurodegenerative disease	Nicotinic ACh agonist	Nootropic agent
302	Phase 2 Clinical	Novartis AG	TCH-346	Parkinson's disease; Motor neuron disease	Metabotropic glutamate receptor 2 agonist	Neuroprotectant; Nootropic agent; Antiparkinsonian
303	Discontinued	Takeda Chemical Industries Ltd	TGP-580	Neurodegenerative disease; Peptic ulcer; Wound healing	FGF-2 agonist	Neuroprotectant
304	Discovery	Thuris Corp	Thurinex	Alzheimer's disease	Amyloid protein deposition inhibitor	Neuroprotectant
305	Discovery	Lonza Group	TK-14	Neurodegenerative disease		Neuroprotectant
306	Discontinued	AVANT Immunotherapeutics Inc	TP-20	Multiple sclerosis; Neurodegenerative disease	Complement factor inhibitor; Selectin antagonist	Cardioprotectant; Immunosuppressant
307	Discovery	Pfizer Inc	Traxoprodil	Neurodegenerative disease; Parkinson's disease	NMDA receptor antagonist	Neuroprotectant; Analgesic; Antiparkinsonian
308	Phase 2 Clinical	Pfizer Inc	Traxoprodil	Cerebrovascular ischemia	NMDA receptor antagonist	Neuroprotectant; Analgesic; Antiparkinsonian
309	No Development Reported	Pharmacia & Upjohn Inc	U-74500A	Neurodegenerative disease	Aminosteroid	Neuroprotectant
310	Discontinued	Pharmacia & Upjohn Co	U-78517F	Alzheimer's disease; Inflammation; Neurodegenerative disease; Cerebrovascular ischemia	Lipid peroxidation inhibitor	Vasoprotectant; Anti-inflammatory; Antioxidant agent

	Highest Dev. Status	Company	Drug	Indication	Mode of Action	Drug Effect
311	Discovery	Pfizer Inc	UK-351666; UK-356464; UK-356297	Alzheimer's disease; Neurodegenerative disease; Parkinson's disease; Peripheral neuropathy	FKBP inhibitors	Antiparkinsonian; Immunosuppressant
312	Research Tool	US National Institute on Drug Abuse	Vanoxerine	Schizophrenia	Dopamine uptake inhibitor	Antipsychotic
313	Discovery	Serono; Vertex Pharmaceuticals Inc	VX-799	Neurodegenerative disease; Cardiovascular disease; Cerebral infarction; Cerebrovascular ischemia	Caspase inhibitor	Apoptosis inhibitor; Neuroprotectant; Vasoprotectant; Anti-inflammatory
314	Discovery	Neurocrine Biosciences Inc; Wyeth	WAY-855	Neurodegenerative disease; Psychosis; Schizophrenia; Cerebrovascular ischemia	EAAT modulator; glutamate receptor modulator	Neuroprotectant; Antipsychotic
315	Discovery	Sterling Winthrop Products Inc	WIB-63480-2	Alzheimer's disease; Huntington's chorea; Epilepsy; Cerebrovascular ischemia	NMDA receptor antagonist	Neuroprotectant
316	No Development Reported	Sterling Winthrop Products Inc	WIN-67500	Neurodegenerative disease	Calpain inhibitor	Neuroprotectant
317	No Development Reported	Sterling Winthrop Products Inc	WIN-68100	Neurodegenerative disease	Calpain inhibitor	Neuroprotectant
318	No Development Reported	Sterling Winthrop Products Inc	WIN-69211	Neurodegenerative disease	Calpain inhibitor	Neuroprotectant
319	Phase 3 Clinical	Sanofi-Synthelabo	Xaliproden	Alzheimer's disease	NGF agonist; 5-HT 1a agonist	Neuroprotectant; Nootropic agent
320	Discontinued	Yamanouchi Pharmaceutical Co Ltd	YM-90K	Cerebrovascular ischemia	AMPA receptor antagonist	Neuroprotectant
321	Phase 3 Clinical	Elan Pharmaceuticals Inc	Ziconotide	Neurodegenerative disease; Cardiac failure; Cardiovascular disease; Cerebrovascular ischemia; Head injury	Calcium channel blocker, N-type	Neuroprotectant, Analgesic; Vasodilatory agent
322	No Development Reported	Yamanouchi Pharmaceutical Co Ltd	Zonampanel	Cerebrovascular ischemia	AMPA receptor antagonist	Neuroprotectant

Glossary

Research Tool: Compounds that are not used as a drug, but needed to investigate the function of a specific compound, which might result in a drug (e.g. Biomarkers for imaging in Alzheimer's Disease).

Discovery: Late research state, preparation for human testing: adaptation of research chemical synthesis (mg) to larger scale (kg), selection of salt form, selection of galenical form, design of clinical proof of concept studies, definition of endpoints, selection of biomarkers for clinical testing, additional safety testing, IND (investigational new drug) filing, clinical ethical review boards.

Phase 1: Clinical testing: tolerance in humans, repeated dosing, some escalation; proof of therapeutic concept or mechanism using scientific evaluation methods in a limited number of volunteers or patients.

Phase 2: Dose-finding studies, statistics, double blind studies.

Phase 3: Proof of efficacy, comparison to standard therapy, statistics, double blind studies with up to thousands of patients. Final phase of testing before registration and license to market.

Phase 4: Exploration of additional indications, other medical properties, can involve >10 000 patients, post-marketing studies as required by authorities.

Sources

'Investigational Drugs database. Copyright Current Drugs 2004'

'The Final Neuroprotection Report, Bolt International Healthcare & Pharmaceutical Research, February 2003'

Disclaimer

The author does not warrant or assume any legal liability or responsibility for the accuracy, completeness, or usefulness of the information in the article. It is not the intention of the author to provide medical advice or to promote or endorse any medical practice, test or program, but rather to provide readers with information to better understand neurodegenerative diseases. The author is not responsible for errors in or omissions of information contained in the article or any actions resulting from the use of such information. Readers are encouraged to confirm the information in the article with other reliable sources.